Gene silencing: a step forward for rare disease therapy
By Dr Dan Williams (Co-founder and CEO of SynaptixBio)
ABB’s robotics ecosystem: advancing lab efficiency in drug discovery
By Drug Target Review
New advances in hormone replacement therapy set to transform care
By Dr Charles P. Virden – CEO of VitalTE, Dr…
Why DNA Damage Response deserves renewed focus in cancer therapy
By Luke Piggott (Principal Scientist - Debiopharm)
New research identifies key gene linked to metabolic liver disease
A team of researchers at Waseda University in Japan has identified a gene called Nwd1 that plays a key role in the development of metabolic dysfunction-associated steatohepatitis (MASH). This discovery could lead to new therapeutic strategies, potentially reshaping the treatment landscape for liver disease.
New Alzheimer’s treatment targets root causes, not just symptoms
Porosome Therapeutics has made a groundbreaking discovery in Alzheimer’s research by targeting the disease’s molecular causes, focusing on restoring secretory and metabolic functions. This approach could not only slow progression but potentially reverse early-stage pathology.
New drug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer’s and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
Why DNA Damage Response deserves renewed focus in cancer therapy
By Luke Piggott (Principal Scientist - Debiopharm)
The evolution of AI in drug discovery: learning from history’s…
By Dr Raminderal Singh (Hitchhikers AI and 20/15 Visioneers, Sujeegar…